Aerie Pharmaceuticals was founded to discover a drug that targets the main cause of elevated intraocular pressure (IOP) in glaucoma–the diseased trabecular meshwork. This intensive effort led to the design of netarsudil, a Rho kinase (ROCK) inhibitor, and the assembly of a proprietary library of thousands of related molecules.
Our medicinal chemists, biologists, engineers, and clinical researchers are focused on drug candidates that leverage our small-molecule drug discovery, formulation, and drug delivery capabilities.
We are building a global pipeline of innovative eye care therapeutics that address unmet needs in ophthalmology.MORE
We have completed and continue to pursue clinical trials that are providing a growing data set on the efficacy and safety of our products.MORE
The results of our R&D activities are regularly published in peer-reviewed journals or presented at leading scientific and medical congresses.MORE